Brodalumab for the treatment of psoriasis
- 21 October 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 12 (12) , 1255-1271
Abstract
Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monoclonal antibody, is currently the most-developed treatment that binds to the IL-17RA. The authors review and provide updates of efficacy and safety by several studies on brodalumab. Areas covered: A PubMed search was performed for relevant literature. Among the trials of brodalumab, the most common adverse events included nasopharyngitis, headache, upper respiratory tract infection, and arthralgia. Suicidal ideation and completed suicides had been observed in the brodalumab programme, although evidence to date was quoted as not suggesting a causal association. Expert commentary: By blocking the IL-17 receptor A, brodalumab antagonizes signaling from IL-17A, IL-17F, IL-17A/F and IL-25, and this probably contributes to the high efficacy observed in clinical trials. Considering the different therapeutic target and the potential biological implications that blocking IL-17RA instead of IL-17A might have, brodalumab may not necessarily belong to the same class that includes secukinumab and ixekizumab, but it may be classified in a distinct group.Keywords
This publication has 51 references indexed in Scilit:
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsBritish Journal of Dermatology, 2012
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 ImmunityScience, 2011
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisScience Translational Medicine, 2010
- Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapyBritish Journal of Dermatology, 2010
- Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaquesThe Journal of Pathology, 2009
- Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque PsoriasisDermatology, 2008
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasisBritish Journal of Dermatology, 2007
- The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper CellsCell, 2006
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005